SMARCA4 Antibody

What is SMARCA4 and what is its biological significance?

SMARCA4, also known as BRG1, BAF190A, SNF2B, and SNF2L4, belongs to the SNF2/RAD54 helicase family. It functions as a transcriptional coactivator that cooperates with nuclear hormone receptors to potentiate transcriptional activation. SMARCA4 is one of two mutually exclusive ATPases present in mammalian SWI/SNF chromatin remodeling complexes .

The protein is a critical component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating calcium-dependent release of repressor complexes and recruitment of activator complexes. Additionally, SMARCA4 is involved in vitamin D-coupled transcription regulation through its association with the WINAC complex, a chromatin-remodeling complex .

SMARCA4's significance extends to cancer biology, as it is frequently mutated in human lung adenocarcinoma. Research has demonstrated that SMARCA4 functions as a tumor suppressor, with its loss potentially leading to malignant transformation and tumor progression in specific cellular contexts .

What are the recommended applications for SMARCA4 antibodies?

SMARCA4 antibodies have been validated for numerous experimental applications. Based on comprehensive validation data, researchers can employ these antibodies in:

How should I validate SMARCA4 antibody specificity?

Validating SMARCA4 antibody specificity is crucial for ensuring reliable experimental results. A comprehensive validation approach includes:

• Western blot analysis using both N- and C-terminal SMARCA4 antibodies to confirm protein size (observed molecular weight of approximately 180-185 kDa) .

• Testing in multiple cell lines with known SMARCA4 expression. Validated cell lines include HeLa, HepG2, K-562, MCF-7, and PC-3 cells .

• Employing SMARCA4 knockout or knockdown systems as negative controls. This approach has been documented in at least 4 publications referenced in the antibody literature .

• Comparative analysis with independent antibodies targeting different epitopes. True SMARCA4 expression is suggested when different antibodies show identical staining patterns, including loss of signal in tumors with SMARCA4 expression loss .

• RNA-sequencing correlation to compare protein detection with transcript levels .

For immunohistochemistry applications specifically, kidney tissue serves as an excellent positive control, as all cells should display at least moderate nuclear SMARCA4 immunostaining. A tumor or cell line with documented SMARCA4 expression loss should be used as a negative control .

How can SMARCA4 antibodies be utilized to study chromatin remodeling mechanisms?

SMARCA4 antibodies provide powerful tools for investigating chromatin remodeling mechanisms, particularly in the context of SWI/SNF complex function. Advanced research approaches include:

• Chromatin Immunoprecipitation followed by sequencing (ChIP-seq): SMARCA4 antibodies have been successfully employed in ChIP applications to map genome-wide binding sites and identify target genes. This approach reveals how SMARCA4-containing complexes regulate chromatin accessibility at specific genomic loci, particularly at lung lineage motifs as demonstrated in research on SMARCA4's role in lung adenocarcinoma .

• Sequential ChIP (Re-ChIP): This technique allows researchers to identify genomic regions bound by multiple factors. By first immunoprecipitating with SMARCA4 antibodies and then with antibodies against other transcription factors or chromatin modifiers, researchers can identify cooperative binding events that regulate gene expression.

• ATAC-seq integration: Combining SMARCA4 ChIP-seq with ATAC-seq (Assay for Transposase-Accessible Chromatin with sequencing) data provides insights into how SMARCA4 loss affects chromatin accessibility. Research has shown that SMARCA4 deficiency results in decreased chromatin accessibility at lung lineage motifs, contributing to tumor progression .

• Co-IP coupled with mass spectrometry: SMARCA4 antibodies can immunoprecipitate intact SWI/SNF complexes, which can then be analyzed by mass spectrometry to identify novel interacting partners or study complex composition changes in different cellular contexts .

SMARCA4 antibodies have been instrumental in demonstrating that SMARCA4 loss impairs the function of all three classes of SWI/SNF complexes, providing mechanistic insight into how its inactivation contributes to cancer progression .

What are the key considerations when using SMARCA4 antibodies in cancer research?

When employing SMARCA4 antibodies in cancer research, several critical considerations must be addressed:

• Cell-type specificity: SMARCA4's tumor suppressive function is dependent on the cell type in which the mutation occurs. Research using genetically engineered mouse models (GEMMs) has shown that SMARCA4 loss sensitizes certain cell populations (CCSP+ cells) within the lung to malignant transformation, while other cell types may respond differently .

• Heterogeneity of expression: In tumor studies, researchers should assess SMARCA4 expression at the single-cell level rather than in bulk samples. Studies have demonstrated that advanced (Grade 4) lesions and metastases universally lack SMARCA4 protein expression, indicating strong selection for complete SMARCA4 loss in highly advanced tumors .

• Antibody validation in cancer tissues: For accurate interpretation, SMARCA4 antibodies should be validated using both positive controls (normal tissues with known expression) and negative controls (tumors with documented SMARCA4 expression loss) .

• Epitope accessibility in different tumor types: Different fixation and antigen retrieval methods may be necessary for optimal staining in various tumor types. For immunohistochemistry applications, suggested protocols include antigen retrieval with TE buffer pH 9.0 or alternatively with citrate buffer pH 6.0 .

• Integration with functional studies: SMARCA4 protein detection should be correlated with functional outcomes. Research has demonstrated that SMARCA4-deficient primary tumors lack lung lineage transcription factor activities and resemble a metastatic cell state, suggesting its role in maintaining differentiation .

Understanding these considerations is essential for correctly interpreting SMARCA4 antibody staining patterns in cancer research and avoiding misinterpretation of experimental results.

How do different epitope targets of SMARCA4 antibodies affect experimental outcomes?

The choice of SMARCA4 antibody based on its epitope target can significantly impact experimental outcomes and data interpretation:

For comprehensive SMARCA4 analysis, researchers should consider using antibodies targeting distinct epitopes, particularly in studies involving potential SMARCA4 mutations or truncations that might affect epitope availability.

Why might I see inconsistent results when using SMARCA4 antibodies in different cell lines?

Inconsistent SMARCA4 antibody results across cell lines can stem from several biological and technical factors:

• Variable SMARCA4 expression levels: Cell lines exhibit intrinsic differences in SMARCA4 expression. Validated positive cell lines for Western blot include HeLa, K-562, HepG2, MCF-7, and PC-3 cells . If testing uncharacterized cell lines, researchers should first establish baseline expression levels.

• SMARCA4 mutations or deletions: Some cell lines may harbor SMARCA4 mutations or deletions that affect epitope recognition. Sequencing data should be consulted when working with cancer cell lines, as SMARCA4 is frequently mutated in human lung adenocarcinoma and other cancers .

• SWI/SNF complex composition variations: SMARCA4 functions within SWI/SNF complexes, and the composition of these complexes varies across cell types. These variations may affect antibody accessibility to SMARCA4 epitopes, particularly in native conditions used for immunoprecipitation or immunofluorescence .

• Cell fixation and permeabilization protocols: For immunofluorescence applications, different cell lines may require optimized fixation and permeabilization protocols. HepG2, HeLa, and HEK-293 cells have been validated for immunofluorescence with specific SMARCA4 antibodies .

• Subcellular localization differences: While SMARCA4 is predominantly nuclear, its distribution pattern may vary with cellular state (proliferation, differentiation, stress). This can affect staining patterns, especially in immunofluorescence applications .

To address these issues, researchers should:

What are the best practices for optimizing SMARCA4 antibody performance in ChIP experiments?

Optimizing SMARCA4 antibody performance in Chromatin Immunoprecipitation (ChIP) experiments requires attention to several critical parameters:

• Antibody selection: Choose antibodies specifically validated for ChIP applications. Multiple publications have documented successful use of certain SMARCA4 antibodies in ChIP experiments . For instance, antibody 21634-1-AP has been cited in 7 publications for ChIP applications .

• Crosslinking optimization: SMARCA4 is part of large chromatin remodeling complexes, making crosslinking efficiency crucial. Optimize formaldehyde concentration (typically 1-1.5%) and crosslinking time (8-15 minutes) for your specific cell type.

• Sonication parameters: SWI/SNF complexes bind to nucleosomes and affect chromatin structure. Optimize sonication conditions to achieve chromatin fragments of 200-500 bp for high-resolution mapping of SMARCA4 binding sites.

• Antibody concentration: Titrate antibody amounts in preliminary experiments. Published protocols have used varying amounts depending on the specific antibody and experimental conditions.

• Washing stringency: Optimize wash buffer composition to reduce background while maintaining specific SMARCA4-chromatin interactions. Consider including non-ionic detergents (NP-40, Triton X-100) at appropriate concentrations.

• Controls: Include the following essential controls:

  • Input chromatin (pre-immunoprecipitation)

  • IgG control from the same species as the SMARCA4 antibody

  • Positive control loci (known SMARCA4 binding sites)

  • Negative control regions (loci not bound by SMARCA4)

  • In SMARCA4 knockout or knockdown systems when available

• Sequential ChIP considerations: For sequential ChIP experiments investigating co-occupancy with other factors, optimize elution conditions from the first immunoprecipitation to preserve epitopes for the second antibody.

By carefully optimizing these parameters, researchers can achieve high-quality ChIP data that accurately reflects SMARCA4 genomic occupancy and its role in chromatin remodeling.

How should I interpret SMARCA4 expression patterns in normal versus tumor tissues?

Interpreting SMARCA4 expression patterns in normal versus tumor tissues requires careful consideration of several factors:

What buffer conditions optimize SMARCA4 antibody performance in different applications?

Optimizing buffer conditions is crucial for maximizing SMARCA4 antibody performance across different experimental applications:

• Western Blot (WB):

  • Sample preparation: RIPA or NP-40 lysis buffers supplemented with protease inhibitors

  • Blocking: 5% non-fat dry milk or BSA in TBST

  • Antibody dilution: Prepare in 5% BSA or milk in TBST at 1:500-1:3000 dilution

  • Washing: TBST (TBS with 0.1% Tween-20)

  • Detection: Compatible with both chemiluminescence and fluorescence-based systems

• Immunohistochemistry (IHC):

  • Antigen retrieval: TE buffer pH 9.0 is recommended; citrate buffer pH 6.0 is an alternative

  • Blocking: 5-10% normal serum from secondary antibody host species

  • Antibody dilution: 1:200-1:800 in blocking buffer

  • Detection systems: Compatible with both DAB and AP-based detection systems

• Immunofluorescence (IF)/ICC:

  • Fixation: 4% paraformaldehyde (10-15 minutes)

  • Permeabilization: 0.1-0.5% Triton X-100 in PBS

  • Blocking: 1-3% BSA with 5-10% normal serum in PBS

  • Antibody dilution: 1:300-1:1200 in blocking buffer

  • Counterstains: Compatible with DAPI nuclear stain

• Immunoprecipitation (IP):

  • Lysis buffer: Non-denaturing conditions using NP-40 or Triton X-100 based buffers

  • Antibody amount: 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate

  • Binding conditions: 4°C overnight rotation

  • Washing: Increasing stringency washes to reduce background

• Chromatin Immunoprecipitation (ChIP):

  • Crosslinking: 1% formaldehyde for 10 minutes

  • Sonication buffer: SDS-containing buffer for chromatin shearing

  • IP buffer: Reduced SDS concentration with non-ionic detergents

  • Washing: Increasingly stringent wash buffers to reduce background

  • Elution: SDS-containing buffer at elevated temperature

• Storage conditions: SMARCA4 antibodies are typically stored in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3. For long-term storage, maintain at -20°C, where they remain stable for one year after shipment. Aliquoting is unnecessary for -20°C storage .

These optimized buffer conditions should be used as starting points and further refined based on specific experimental requirements and the particular SMARCA4 antibody being used.

How can I effectively use SMARCA4 antibodies in multiplexed immunofluorescence studies?

Multiplexed immunofluorescence with SMARCA4 antibodies allows simultaneous visualization of multiple proteins and assessment of their spatial relationships. For optimal results in these complex studies:

• Antibody selection and validation:

  • Choose SMARCA4 antibodies specifically validated for immunofluorescence. The 21634-1-AP antibody has been validated in HepG2, HeLa, and HEK-293 cells .

  • Confirm compatibility with other primary antibodies in your panel (different host species or isotypes are preferable).

  • Validate each antibody individually before combining them.

• Sequential staining approach:

  • For challenging combinations, consider sequential staining with intermediate fixation steps.

  • When studying SMARCA4 with other nuclear proteins, optimize signal separation using spectral imaging or careful fluorophore selection.

  • Since SMARCA4 is predominantly nuclear, combine with cytoplasmic or membrane markers for better spatial context.

• Signal amplification strategies:

  • For low SMARCA4 expression, employ tyramide signal amplification (TSA) or similar methods.

  • Balance amplification across all markers to prevent one signal from overwhelming others.

  • When using signal amplification, include appropriate controls to ensure specificity.

• Imaging considerations:

  • Use confocal or super-resolution microscopy for optimal spatial resolution of nuclear SMARCA4.

  • Employ spectral unmixing for closely overlapping fluorophores.

  • Include single-stained controls for accurate spectral unmixing and bleed-through correction.

• Quantification approaches:

  • Develop algorithms that accurately segment nuclei for SMARCA4 quantification.

  • Consider intensity, area, and pattern of SMARCA4 staining in your analysis.

  • Correlate SMARCA4 levels with other markers at the single-cell level.

• Recommended applications:

  • Co-localization studies with other SWI/SNF complex components

  • Assessment of SMARCA4 in relation to transcription factors

  • Correlation of SMARCA4 expression with cell-type markers in heterogeneous tissues

  • Evaluation of SMARCA4 status in relation to proliferation or differentiation markers

By implementing these strategies, researchers can effectively incorporate SMARCA4 antibodies into multiplexed immunofluorescence studies, providing valuable insights into its role in chromatin regulation and disease processes.

What sample preparation techniques are essential for reliable SMARCA4 detection in FFPE tissues?

Reliable detection of SMARCA4 in formalin-fixed paraffin-embedded (FFPE) tissues requires meticulous attention to sample preparation:

• Fixation parameters:

  • Optimal fixation: 10% neutral buffered formalin for 24-48 hours

  • Avoid prolonged fixation (>72 hours) which can mask SMARCA4 epitopes

  • Consistent fixation across samples is crucial for comparative studies

• Antigen retrieval optimization:

  • Heat-induced epitope retrieval (HIER) is essential for SMARCA4 detection

  • Recommended primary approach: TE buffer pH 9.0

  • Alternative approach: Citrate buffer pH 6.0

  • Optimization of retrieval time (typically 15-30 minutes) and temperature is critical

• Section preparation:

  • Optimal section thickness: 4-5 μm

  • Fresh-cut sections yield better results than stored slides

  • If using stored sections, limit storage time and maintain in appropriate conditions

• Blocking strategies:

  • Endogenous peroxidase blocking: 3% H₂O₂ for 10 minutes

  • Protein blocking: 5-10% normal serum or commercial blocking solutions

  • For tissues with high background, include additional blocking steps (avidin/biotin blocking if using biotin-based detection)

• Antibody incubation:

  • Recommended dilution range: 1:200-1:800

  • Optimal incubation temperature: 4°C overnight or room temperature for 1-2 hours

  • Use antibody diluent with background-reducing components

• Detection system selection:

  • Polymer-based detection systems offer better sensitivity than biotin-based methods

  • Amplification systems should be considered for tissues with low SMARCA4 expression

  • DAB is the recommended chromogen for optimal signal-to-noise ratio

• Controls and validation:

  • Positive tissue control: Kidney tissue (all cells should display at least moderate nuclear SMARCA4 immunostaining)

  • Negative control: Tumor with documented SMARCA4 expression loss

  • Include on-slide controls whenever possible for direct comparison

• Interpretation guidelines:

  • SMARCA4 shows nuclear localization

  • Evaluate staining intensity and percentage of positive cells

  • Compare with normal adjacent tissue when available

  • Consider heterogeneity of expression within tumor samples

Following these detailed preparation techniques will maximize the likelihood of obtaining reliable, reproducible SMARCA4 immunostaining in FFPE tissues for accurate assessment in research and diagnostic applications.

How has SMARCA4 antibody technology advanced our understanding of chromatin biology and cancer?

SMARCA4 antibody technology has significantly advanced our understanding of chromatin biology and cancer through several key contributions:

• Chromatin remodeling mechanisms: SMARCA4 antibodies have enabled detailed mapping of SWI/SNF complex binding sites across the genome, revealing how these complexes regulate chromatin accessibility. Research has demonstrated that SMARCA4 loss impairs the function of all three classes of SWI/SNF complexes, resulting in decreased chromatin accessibility at specific genomic loci, particularly at lung lineage motifs .

• Cell-type specific tumor suppression: Through immunohistochemical analyses with SMARCA4 antibodies, researchers have discovered that SMARCA4's tumor suppressive function is cell-type dependent. While SMARCA4 loss inhibits tumor progression in many contexts, a subset of SMARCA4-deficient transformed cells can give rise to highly advanced and metastatic tumors .

• Tumor progression mechanisms: SMARCA4 antibody staining has revealed that Grade 4 lesions and metastases from SMARCA4-deficient tumors universally lack SMARCA4 protein expression, indicating strong selection for complete SMARCA4 loss in advanced tumors. This finding has provided critical insight into the mechanisms of tumor progression and metastasis .

• Transcriptional regulation: ChIP studies using SMARCA4 antibodies have illuminated how this protein regulates transcription factor activities. SMARCA4-deficient primary tumors lack lung lineage transcription factor activities and resemble a metastatic cell state, demonstrating SMARCA4's role in maintaining cellular differentiation .

• Diagnostic applications: The development of validated SMARCA4 antibodies with consistent staining patterns has enabled more accurate diagnosis of SMARCA4-deficient cancers. True SMARCA4 expression can now be reliably detected or its loss confirmed through comparison with independent antibodies showing identical staining patterns .

The continued refinement of SMARCA4 antibody technology, including the development of recombinant monoclonal antibodies with enhanced specificity and reproducibility, promises to further advance our understanding of chromatin biology and the role of SMARCA4 in health and disease.

What future directions might SMARCA4 antibody research take?

The field of SMARCA4 antibody research is poised for several important future developments:

• Single-cell applications: Development of SMARCA4 antibodies optimized for single-cell protein analysis technologies will allow researchers to examine heterogeneity in SMARCA4 expression and function at unprecedented resolution. This approach will be particularly valuable for understanding tumor heterogeneity and identifying rare cell populations with altered SMARCA4 activity.

• Proximity labeling approaches: Next-generation SMARCA4 antibody tools compatible with proximity labeling methods (BioID, APEX) will enable more comprehensive mapping of SMARCA4 protein interaction networks in living cells. These approaches will provide dynamic information about how SMARCA4-containing complexes respond to various cellular stimuli.

• Therapeutic targeting validation: As SMARCA4-deficient cancers represent potential targets for synthetic lethal therapeutic approaches, highly specific SMARCA4 antibodies will be essential for patient stratification and treatment response monitoring in clinical trials. Development of companion diagnostic antibodies will be a critical focus.

• Post-translational modification-specific antibodies: Development of antibodies that specifically recognize distinct SMARCA4 post-translational modifications will provide deeper insight into how SMARCA4 activity is regulated in different contexts. These tools will help elucidate mechanisms of SMARCA4 activation and inactivation.

• Intrabody development: Engineering of intrabodies (intracellular antibodies) against SMARCA4 could enable live-cell imaging of SMARCA4 dynamics and potentially allow for acute inhibition of specific SMARCA4 functions. This approach would complement genetic knockout strategies by allowing temporal control of inhibition.

• Cross-platform validation: Standardization of SMARCA4 antibody validation across multiple platforms (IHC, IF, ChIP, mass cytometry) will improve reproducibility and data integration in SMARCA4 research. This will be particularly important for translational applications bridging basic research and clinical implementation.